Drugs / DAZCAPISTAT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04001998 | Feb → Jun 2021 | — | Blade Therapeutics | Withdrawn | No outcome recorded |
| Phase 1 | NCT03559166 | Jul 2018 → Oct 2019 | — | Blade Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04244825 | Dec 2019 → Sep 2020 | idiopathic pulmonary fibrosis | Blade Therapeutics | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04334460 Comparator | May → Nov 2020 | COVID-19 | Blade Therapeutics | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAZCAPISTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095225 ↗ |
| Known as | BLD-2660 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03559166 ↗ |
| Action | Inhibit | “inhibitor of calpain (CAPN) 1, 2, and 9” NCT04334460 ↗ |
| Modality | Small molecule | “small molecule inhibitor” NCT04334460 ↗ |
| Route | Oral | “Single oral dose of BLD-2660 or placebo capsule administered to healthy volunteers” NCT03559166 ↗ |